U.S. Patent Application No. 10/070,882 Amendment and Response to Non-Final Office Action Page 2

Amendments to the Specification

On Page 1, at the beginning of line 1 prior to Recombinant microorganisms, please insert the following heading:

--TITLE OF THE INVENTION--.

On Page 1, between lines 1 and 3, please insert the following:

-- CROSS REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. §371 of PCT/GB96/00571, filed March 13, 1996--.

On Page 1, between lines 1 and 3, after cross reference to related applications, please insert the heading:

--BACKGROUND OF THE INVENTION--.

On Page 4, between lines 4 and 6, please insert the heading --OBJECTS OF THE INVENTION--.

Page 4, between lines 31 and 33, insert the heading -- DETAILED DESCRIPTION OF THE INVENTION--.

On Page 12, between lines 3 and 5, insert the heading --BRIEF DESCRIPTION OF THE DRAWINGS--.

Please replace the following paragraph on page 12, lines 16-18, of the instant application as follows:

"Figure 3a and 3b shows graphs illustrating IgG serum antibody levels in mice to the carrier bacterium, (Figure 3a) and to the F1 antigen (Figure 3b), 21, 28 and 98 days after immunization;"

Please replace the following paragraph on page 12, lines 33-35, of the instant application as follows:

"Figure 7a and 7b shows the results of elispot analysis of Peyer's patch cells and in particular the IgA response against F1 antigen (Figure 7a) and Salmonella (Figure 7b)."

Please replace lines 17-18 on page 19 of the instant application as follows:

"After incubation overnight at 4° C, plates were washed three times in PBS with 0.02% (v/v) TWEEN 20^{TM} (Polysorbate 20)"

Please insert the following paragraph on page 24, line 1, of the instant application:
--ABSTRACT

A method of enhancing expression of a desired protein at mucosal effector sites, said method comprising placing the protein to be expressed under the control of a promoter having SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4 or a fragment or variant or any of these which has promoter activity, and causing expression in mucosal cells. Constructs used in the methods, as well as suitable recombinant gut-colonising microorganisms such as a *Salmonella spp*. are also described and claimed. Such organisms are useful in the preparation of vaccines--.